Literature DB >> 8799681

Current drug treatment and treatment patterns with antihypertensive drugs.

E D Freis1, V Papademetriou.   

Abstract

The 4 major classes of antihypertensive drugs are diuretics, beta-blockers, ACE inhibitors and calcium antagonists. The diuretics have recently regained prominence, largely due to the results of recent controlled trials. These trials in elderly patients demonstrated that low-dose diuretics were effective not only in preventing stroke but also in greatly reducing coronary-related events. Diuretics also decrease left ventricular mass more than the other major drug classes. In addition, they are the most effective drugs for use in combination therapy. By contrast, the safety of calcium antagonists has recently been questioned because of report of increased coronary morbidity and mortality. However, these adverse events may be restricted to the short-acting preparations, especially nifedipine, which causes cardiac stimulation. ACE inhibitors, like beta-blockers, are not only effective in reducing blood pressure, particularly when combined with a diuretic, but also improve angina and decrease postinfarction mortality. They also benefit congestive heart failure, stabilise or improve renal function in hypertensive and diabetic nephropathy and reduce albuminuria. Beta-Blockers are especially effective in reducing sudden cardiac death in patients with coronary heart disease, particularly in postinfarction patients. Final proof of the relative effectiveness of these drugs in preventing morbidity and mortality must await the outcome of large comparative trials currently under way. A recent national survey in the US found that more than 75% of hypertensive patients did not have their hypertension completely controlled. Possible reasons for this disturbing statistic are discussed along with suggestions for improvement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799681     DOI: 10.2165/00003495-199652010-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  114 in total

Review 1.  Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics.

Authors:  M Moser; J F Setaro
Journal:  Eur Heart J       Date:  1991-09       Impact factor: 29.983

Review 2.  Is there a role for the vascular renin-angiotensin system in the determination of vascular structure?

Authors:  M J Mulvany
Journal:  Blood Vessels       Date:  1991

3.  Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

Authors:  A P Douglas-Jones; J M Cruickshank
Journal:  Br Med J       Date:  1976-04-24

Review 4.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

5.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.

Authors:  I Crozier; H Ikram; N Awan; J Cleland; N Stephen; K Dickstein; M Frey; J Young; G Klinger; L Makris
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

6.  Calcium antagonists and sodium balance: effect of changes in sodium intake and of the addition of a thiazide diuretic on the blood pressure lowering effect of nifedipine.

Authors:  F P Cappuccio; N D Markandu; G A MacGregor
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; R A Preston; W C Cushman; B M Massie; E D Freis; M S Kochar; R J Hamburger; C Fye; R Lakshman
Journal:  Arch Intern Med       Date:  1995-09-11

8.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

9.  The natural history of borderline isolated systolic hypertension.

Authors:  A Sagie; M G Larson; D Levy
Journal:  N Engl J Med       Date:  1993-12-23       Impact factor: 91.245

10.  Effect of verapamil on glucose response to intravenous injection of glucagon and insulin in healthy subjects.

Authors:  S Röjdmark; D E Andersson; R Hed; L Sundblad
Journal:  Horm Metab Res       Date:  1980-07       Impact factor: 2.936

View more
  5 in total

Review 1.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Nebivolol in the management of essential hypertension: a review.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 3.  Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.

Authors:  J C Gillis; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  The Importance of Systolic Blood Pressure Control and Cardiovascular Disease Prevention.

Authors:  Jan N. Basile
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-08

Review 5.  Hypertension in the elderly: a review of the importance of systolic blood pressure elevation.

Authors:  Jan Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Mar-Apr       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.